✦ LIBER ✦

201 RATIONALE AND DESIGN OF THE PARKFIT STUDY: A RANDOMIZED CONTROLLED TRIAL TO INCREASE PHYSICAL ACTIVITY IN PATIENTS WITH PARKINSON'S DISEASE

✍ Scribed by A. Speelman; M. van Nimwegen; K. Smulders; S. Overeem; G. Borm; F. Backx; B. Bloem; M. Munneke

Book ID: 117754262
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 44 KB
Volume: 16
Category: Article
ISSN: 1353-8020
DOI: 10.1016/s1353-8020(10)70202-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Design and baseline characteristics of t

Design and baseline characteristics of the ParkFit study, a randomized controlled trial evaluating the effectiveness of a multifaceted behavioral program to increase physical activity in Parkinson patients

✍ Marlies van Nimwegen; Arlène D Speelman; Katrijn Smulders; Sebastiaan Overeem; G 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 387 KB

Design and baseline characteristics of t

Design and baseline characteristics of the ParkFit study: a randomized controlled trial evaluating the effectiveness of a multifaceted behavioral program to increase physical activity in Parkinson patients1)

✍ Berry Middel 📂 Article 📅 2011 🏛 Springer-Verlag ⚖ 91 KB

The 'Women's Lifestyle Study', 2-year ra

The 'Women's Lifestyle Study', 2-year randomized controlled trial of physical activity counselling in primary health care: rationale and study design

✍ Sally B Rose; Beverley A Lawton; C Raina Elley; Anthony C Dowell; Anna J Fenton 📂 Article 📅 2007 🏛 BioMed Central 🌐 English ⚖ 275 KB

Design and rationale of a randomized con

Design and rationale of a randomized controlled trial to reduce cardiovascular disease risk for patients with bipolar disorder

✍ David E. Goodrich; Amy M. Kilbourne; Zongshan Lai; Edward P. Post; Nicholas W. B 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 616 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

✍ C. Warren Olanow; Robert A. Hauser; Joseph Jankovic; William Langston; Anthony L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

## Abstract A neuroprotective therapy is the single most important unmet medical need in Parkinson's disease. Several promising agents in the laboratory have been tested in the clinic, but none has been established in clinical trials to have a disease modifying effect despite positive results becau

The MINERVA study design and rationale:

The MINERVA study design and rationale: A controlled randomized trial to assess the clinical benefit of minimizing ventricular pacing in pacemaker patients with atrial tachyarrhythmias

✍ Reinhard C. Funck; Giuseppe Boriani; Antonis S. Manolis; Helmut Püererfellner; L 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 241 KB